Details

Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) - Canada.ca

Metadata and links for an archived snapshot.

Source: Health Canada
Date: Jan 3, 2026 · edition #6
Timestamp: 2026-01-03T12:16:31.897Z
Language: en
Original URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=false
Replay URL: https://replay.healtharchive.ca/job-6/20260103121631/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=false#ha_snapshot=446568
ID: 446568
Status: 200
Type: text/html

Independent archive · Not an official government website. For up-to-date recommendations, always consult the official source website.

Other snapshots